Equities

Shanghai Serum Bio-Technology Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Shanghai Serum Bio-Technology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)26.03
  • Today's Change-0.02 / -0.08%
  • Shares traded990.75k
  • 1 Year change+48.07%
  • Beta0.9806
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
ASSETS
Cash And Short Term Investments833874933
Total Receivables, Net38238.66
Total Inventory434555
Prepaid expenses2.977.240.51
Other current assets, total------
Total current assets916949997
Property, plant & equipment, net160128117
Goodwill, net------
Intangibles, net232424
Long term investments--1717
Note receivable - long term------
Other long term assets12----
Total assets1,1201,1281,166
LIABILITIES
Accounts payable1.313.644.28
Accrued expenses9.191717
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.290.761.37
Other current liabilities, total8.833.594.17
Total current liabilities202527
Total long term debt4.001212
Total debt4.301314
Deferred income tax0.915.455.67
Minority interest------
Other liabilities, total------
Total liabilities254345
SHAREHOLDERS EQUITY
Common stock108108108
Additional paid-in capital878878871
Retained earnings (accumulated deficit)109100142
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity1,0961,0861,122
Total liabilities & shareholders' equity1,1201,1281,166
Total common shares outstanding108108108
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.